MTOR and endometrial cancer: The strategies including letrozole combined with phosphoinositide 3-kinase (PI3K) inhibitors and mammalian target of rapamycin (mTOR) inhibitors, and the potential synergism has already been demonstrated in breast and endometrial cancers (37–40).